Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobsen, P.
Right arrow Articles by Parving, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, P.
Right arrow Articles by Parving, H.-H.
J Am Soc Nephrol 14:992-999, 2003
© 2003 American Society of Nephrology

Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy

Peter Jacobsen*, Steen Andersen*, Berit R. Jensen* and Hans-Henrik Parving*,{dagger}

*Steno Diabetes Center, Gentofte, Denmark and {dagger}Faculty of Health Science, University of Aarhus, Denmark.

Correspondence to Dr. Peter Jacobsen, Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Phone: 45-44-43-90-97; Fax: 45-44-43-81-60;

ABSTRACT. Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in diabetic patients. This study tested whether dual blockade of the renin-angiotensin system (RAS) with both an angiotensin-converting enzyme (ACE) inhibitor (ACE-I) and an Angiotensin-II receptor blocker (ARB) is superior to either drug alone in type I diabetic patients with diabetic nephropathy (DN). A randomized double-blind crossover trial was performed with 8-wk treatment with placebo, 20 mg of benazepril once daily, 80 mg of valsartan once daily, and the combination of 20 mg of benazepril and 80 mg of valsartan. Twenty type I diabetic patients with DN were included. At the end of each treatment period, albuminuria, 24-h BP, and GFR were measured. Eighteen patients completed the study. Placebo values were: albuminuria [mean (95% CI)], 701 (490 to 1002) mg/24 h; BP [mean (SEM)], 144 (4)/79 (2) mmHg, and GFR [mean (SEM)], 82 (7) ml/min per 1.73 m2. Treatment with benazepril, valsartan, or dual blockade significantly reduced albuminuria and BP compared with placebo. Benazepril and valsartan were equally effective. Dual blockade induced an additional reduction in albuminuria of 43 % (29 to 54 %) compared with any type of monotherapy, and a reduction in systolic BP of 6 (0 to 13) mmHg and 7 (1 to 14) mmHg (versus benazepril and valsartan, respectively) and a reduction of 7 (4 to 10) mmHg diastolic compared with both monotherapies. GFR was reversibly reduced on dual blockade compared with monotherapy and placebo. All treatments were safe and well tolerated. In conclusion, dual blockade of the RAS may offer additional renal and cardiovascular protection in type I diabetic patients with DN. E-mail: pkjacobsen@dadlnet.dk




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. Abutaleb
ONTARGET should not be over interpreted
Nephrol. Dial. Transplant., November 23, 2009; (2009) gfp633v1.
[Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. Berl
Review: Renal protection by inhibition of the renin-angiotensin-aldosterone system
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 1 - 8.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
S. Basi, P. Fesler, A. Mimran, and J. B. Lewis
Microalbuminuria in Type 2 Diabetes and Hypertension: A marker, treatment target, or innocent bystander?
Diabetes Care, February 1, 2008; 31(Supplement_2): S194 - S201.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Kunz, C. Friedrich, M. Wolbers, and J. F.E. Mann
Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease
Ann Intern Med, January 1, 2008; 148(1): 30 - 48.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. L. Linas
Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S17 - S23.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. F. Hou, D. Xie, X. Zhang, P. Y. Chen, W. R. Zhang, M. Liang, Z. J. Guo, and J. P. Jiang
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1889 - 1898.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. B.A. Eijkelkamp, Z. Zhang, G. Remuzzi, H.-H. Parving, M. E. Cooper, W. F. Keane, S. Shahinfar, G. W. Gleim, M. R. Weir, B. M. Brenner, et al.
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1540 - 1546.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Fernandez-Juarez, V. Barrio, S. G. de Vinuesa, M. Goicoechea, M. Praga, and J. Luno
Dual Blockade of the Renin-Angiotensin System in the Progression of Renal Disease: The Need for More Clinical Trials
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S250 - S254.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
K. A. Griffin and A. K. Bidani
Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade
Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1054 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Kobayashi, Y. Hayashi, K. Taguchi, T. Matsumoto, and K. Kamata
ANG II enhances contractile responses via PI3-kinase p110{delta} pathway in aortas from diabetic rats with systemic hyperinsulinemia
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H846 - H853.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. K. Jacobsen, P. Rossing, and H.-H. Parving
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 2030 - 2031.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
S. G. Tsouli, E. N. Liberopoulos, D. N. Kiortsis, D. P. Mikhailidis, and M. S. Elisaf
Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 1 - 15.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. H. Song, S. H. Cha, H. J. Lee, S. W. Lee, G. H. Park, S. W. Lee, and M.-J. Kim
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-{beta} in type 2 diabetic patients with advanced kidney disease
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 683 - 689.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. J. Coppey, E. P. Davidson, T. W. Rinehart, J. S. Gellett, C. L. Oltman, D. D. Lund, and M. A. Yorek
ACE Inhibitor or Angiotensin II Receptor Antagonist Attenuates Diabetic Neuropathy in Streptozotocin-Induced Diabetic Rats
Diabetes, February 1, 2006; 55(2): 341 - 348.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. De, G. Das, K. Harley, and H. Nair
Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience
The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 23 - 28.
[Abstract] [PDF]

Home page
 HypertensionHome page
T. W.R. Doulton, F. J. He, and G. A. MacGregor
Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension
Hypertension, May 1, 2005; 45(5): 880 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. H. Andersen, Per. L Poulsen, S. T. Knudsen, S. H. Poulsen, H. Eiskjaer, K. W. Hansen, K. Helleberg, and C. E. Mogensen
Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes: The CALM II study
Diabetes Care, February 1, 2005; 28(2): 273 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S M Marshall
Recent advances in diabetic nephropathy
Postgrad. Med. J., November 1, 2004; 80(949): 624 - 633.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. D Coyle, S. F Gardner, and C M. White
The Renal Protective Effects of Angiotensin II Receptor Blockers in Type 2 Diabetes Mellitus
Ann. Pharmacother., October 1, 2004; 38(10): 1731 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. Erman, S. Veksler, U. Gafter, G. Boner, C. Wittenberg, and D. J. van Dijk
Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor {beta}1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2004; 5(3): 146 - 151.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
V. L Wade and B. L Gleason
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Ann. Pharmacother., July 1, 2004; 38(7): 1278 - 1282.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673